Zhang Miao, Zhu Huaiping, Ding Ye, Liu Zhaoyu, Cai Zhejun, Zou Ming-Hui
From the Section of Molecular Medicine, Department of Medicine, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma 73104 and.
the Center for Molecular and Translational Medicine, Georgia State University, Atlanta, Georgia 30302-5035.
J Biol Chem. 2017 May 12;292(19):7888-7903. doi: 10.1074/jbc.M117.779447. Epub 2017 Mar 22.
Monocyte-to-macrophage differentiation, which can be initiated by physiological or atherogenic factors, is a pivotal process in atherogenesis, a disorder in which monocytes adhere to endothelial cells and subsequently migrate into the subendothelial spaces, where they differentiate into macrophages and macrophage-derived foam cells and cause atherosclerotic lesions. However, the monocyte-differentiation signaling pathways that are activated by atherogenic factors are poorly defined. Here we report that the AMP-activated protein kinase α1 (AMPKα1) in monocytes promotes atherosclerosis by increasing monocyte differentiation and survival. Exposure of monocytes to oxidized low-density lipoprotein, 7-ketocholesterol, phorbol 12-myristate 13-acetate, or macrophage colony-stimulated factor (M-CSF) significantly activated AMPK and promoted monocyte-to-macrophage differentiation. M-CSF-activated AMPK is via M-CSF receptor-dependent reactive oxygen species production. Consistently, genetic deletion of AMPKα1 or pharmacological inhibition of AMPK blunted monocyte-to-macrophage differentiation and promoted monocyte/macrophage apoptosis. Compared with apolipoprotein E knock-out () mice, which show impaired clearing of plasma lipoproteins and spontaneously develop atherosclerosis, /α mice showed reduced sizes of atherosclerotic lesions and lesser numbers of macrophages in the lesions. Furthermore, aortic lesions were decreased in mice transplanted with /α bone marrow and in myeloid-specific AMPKα1-deficient mice. Finally, rapamycin treatment, which abolished delayed monocyte differentiation in /α mice, lost its atherosclerosis-lowering effects in these mice. Mechanistically, we found that AMPKα1 regulates FoxO3-dependent expression of both LC3 and ULK1, which are two important autophagy-related markers. Rapamycin treatment increased FoxO3 activity as well as LC3 and ULK1 expressions in macrophages from α mice. Our results reveal that AMPKα1 deficiency impairs autophagy-mediated monocyte differentiation and decreases monocyte/macrophage survival, which attenuates atherosclerosis in mice .
单核细胞向巨噬细胞的分化可由生理因素或致动脉粥样硬化因素引发,是动脉粥样硬化形成过程中的关键环节。动脉粥样硬化是一种病症,在此病症中,单核细胞黏附于内皮细胞,随后迁移至内皮下间隙,在那里它们分化为巨噬细胞和巨噬细胞源性泡沫细胞,并引发动脉粥样硬化病变。然而,由致动脉粥样硬化因素激活的单核细胞分化信号通路尚不清楚。在此我们报告,单核细胞中的AMP激活蛋白激酶α1(AMPKα1)通过增加单核细胞分化和存活来促进动脉粥样硬化。将单核细胞暴露于氧化型低密度脂蛋白、7-酮胆固醇、佛波酯12-肉豆蔻酸酯13-乙酸酯或巨噬细胞集落刺激因子(M-CSF)中可显著激活AMPK并促进单核细胞向巨噬细胞的分化。M-CSF激活的AMPK是通过M-CSF受体依赖性活性氧生成实现的。一致地,AMPKα1的基因缺失或AMPK的药理学抑制减弱了单核细胞向巨噬细胞的分化并促进了单核细胞/巨噬细胞凋亡。与载脂蛋白E基因敲除()小鼠相比,后者表现出血浆脂蛋白清除受损并自发发展为动脉粥样硬化,/α小鼠的动脉粥样硬化病变尺寸减小,病变中的巨噬细胞数量减少。此外,移植了/α骨髓的小鼠以及髓系特异性AMPKα1缺陷的小鼠的主动脉病变减少。最后,雷帕霉素治疗消除了/α小鼠中延迟的单核细胞分化,在这些小鼠中失去了其降低动脉粥样硬化的作用。从机制上讲,我们发现AMPKα1调节FoxO3依赖性的LC3和ULK1的表达,这两者是两个重要的自噬相关标志物。雷帕霉素治疗增加了α小鼠巨噬细胞中FoxO3的活性以及LC3和ULK1的表达。我们的结果表明,AMPKα1缺陷损害了自噬介导的单核细胞分化并降低了单核细胞/巨噬细胞的存活,这减轻了小鼠的动脉粥样硬化。